Stephenson Cancer Center

Oklahoma City, Oklahoma 73117

14 studies enrolling now · 114 studies all time

What they study most

Acinar Cell Carcinoma, Acquired Thrombotic Thrombocytopenic Purpura (aTTP), Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Advanced Breast Cancer, Advanced Cancer, Advanced Cancers Associated With Mesothelin Expression, Advanced Malignancies, Advanced Melanoma, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Colorectal Cancer

Studies at this site

• JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC — Recruiting now
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer — Recruiting now
• Advanced or Recurrent Solid Tumors Treated With SHetA2 — Recruiting now
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors — Recruiting now
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — Recruiting now
• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer — Recruiting now
• Study of XB010 in Subjects With Solid Tumors — Recruiting now
• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer — Recruiting now
• The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer — Recruiting now
• QTX3034 in Patients With KRAS G12D Mutation — Recruiting now
• Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy — Recruiting now
• A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors — Recruiting now
• A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib — Recruiting now
• Study of SGR-3515 In Participants With Advanced Solid Tumors. — Recruiting now
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling
• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies — Running, not enrolling
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies — Stopped early
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
• DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) — Running, not enrolling
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) — Running, not enrolling
• PALbociclib CoLlaborative Adjuvant Study — Running, not enrolling
• Nebulized AER101 in Pre-op NSCLC — Starting soon
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) — Running, not enrolling
• High Dose Omeprazole in Patients With Pancreatic Cancer — Stopped early
• Identify microRNAs in Cachexia in Pancreatic Carcinoma — Stopped early
• Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors — Stopped early
• CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer — Running, not enrolling
• "QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer — Running, not enrolling
• Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer — Running, not enrolling
• A Study of ZW191 in Participants With Solid Tumors — Running, not enrolling
• INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) — Running, not enrolling
• Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion — Running, not enrolling
• Smoking Cessation in Women With Gynecological Conditions — Completed
• RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer — Stopped early
• A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies — Completed
• Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) — Completed
• A Study of DF6002 Alone and in Combination With Nivolumab — Completed
• Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma — Running, not enrolling
• A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer — Running, not enrolling
• Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer — Running, not enrolling
• Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population — Running, not enrolling
• A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib — Running, not enrolling
• A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface — Completed
• A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours — Completed
• This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. — Completed
• Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers — Stopped early
• Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) — Stopped early
• A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors — Stopped early
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression — Completed